Previous 10 | Next 10 |
Charles River Laboratories ( NYSE: CRL ) traded ~1% lower pre-market Thursday after Jefferies downgraded the non-clinical contract research organization to Hold from Buy, noting concerns on biotech funding and supply constraints. Despite signs of stability, the biotech funding...
Company will launch the eXpDNA Platform at Phacilitate Advanced Therapies Week Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its eXpDNA™ plasmid platform, established from the Company’s contract development and manufacturing (CDMO...
Charles River Laboratories ( NYSE: CRL ) has sold its Avian Vaccine Services business to private equity firm Arlington Capital Partners. The business, now AVS Bio, will operate independently as a standalone platform for Arlington, serving the biologic manufacturing and bioprocessi...
Summary Ariel Investments’ 13F portfolio value decreased from $10.02B to $9.11B this quarter. They increased Zebra Technologies, Equity Commonwealth, and Generac Holdings while reducing Adtalem Global Education, Snap-on, and J. M. Smucker. The top three positions are Baidu, M...
Summary Halvorsen's 13F portfolio value decreased marginally from $21.86B to $21.66B this quarter. The number of positions increased from 82 to 88. Viking Global increased Elevance Health, Visa, and McKesson while decreasing T-Mobile US, Parker Hannifin, and Fortive. They also dropped A...
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the re-appointment of Craig B. Thompson, M.D., former President and Chief Executive Officer, Memorial Sloan-Kettering Cancer Center, to its Board of Directors. Dr. Thompson previously served as a member of Charles River...
Next generation robotic endotoxin testing system boosts manufacturing productivity in the lab Charles River Laboratories International, Inc. (NYSE: CRL) launches the Endosafe ® Nexus 200™ , expanding its robust endotoxin testing portfolio. The Nexus 200 is the next e...
Charles River Laboratories International, Inc. (NYSE: CRL) recently opened the first Charles River Accelerator and Development Lab (CRADL®) location in Chicago, expanding contract vivarium space for the biopharmaceutical industry in Illinois. CRADL Chicago is located in F...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including: Jefferies 2022 London Healthcare Conference in London, England on Wednesday, November 16 th , at 10:20 a.m. GMT (5:20 a.m. ET); and ...
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
Charles River Laboratories International Inc. Website:
Clinical trials for AAV9 gene therapy bolstered with plasmid and viral vector CDMO expertise Charles River Laboratories International, Inc. (NYSE: CRL) announced today a collaboration with the FOXG1 Research Foundation (FRF) highlighting the patient advocacy group’s model t...
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Aut...
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7 th , at 9:00 a.m. ET. Investors wi...